Akero Therapeutics, Inc.
AKRO
Rang în acțiuni
#3737
Akero Therapeutics, Inc. is a biopharmaceutical firm dedicated to addressing... Akero Therapeutics, Inc. is a biopharmaceutical firm dedicated to addressing cardio-metabolic disorders, with a specific focus on nonalcoholic steatohepatitis (NASH). Its primary objective is the creation of therapeutic agents aimed at re-establishing metabolic equilibrium and enhancing overall well-being. The company's flagship investigational drug is efruxifermin (EFX), a synthetic analog of fibroblast growth factor 21. EFX is designed to shield cells from stress and modulate the systemic metabolism of fats, carbohydrates, and proteins throughout the body. This promising compound is currently undergoing evaluation in a Phase 2a clinical investigation, known as the BALANCED study, for individuals diagnosed with biopsy-confirmed NASH. Originally established as Pippin Pharmaceuticals, Inc., the organization rebranded as Akero Therapeutics, Inc. in May 2018. Founded in 2017, Akero Therapeutics maintains its corporate headquarters in South San Francisco, California.
Preț acțiune
$54.65
Ultima sincronizare: 2025-12-09
Capitalizare de piață
$4.50B
Schimbare (1 zi)
0.00%
Schimbare (1 an)
1.37%
Țară
US
Tranzacționează Akero Therapeutics, Inc. (AKRO)
Categorie
Healthcare
Raport P/B pentru Akero Therapeutics, Inc. (AKRO)
Raport P/B la data de October 2026 TTM: 4.68
Conform celor mai recente rapoarte financiare și prețului acțiunilor Akero Therapeutics, Inc., raportul P/B actual (TTM) este 4.68. La sfârșitul anului 2023, compania avea un P/B de 2.29.
Istoricul raportului P/B pentru Akero Therapeutics, Inc. din 2017 până în 2026
Raport P/B la sfârșitul fiecărui an
| An | Raport P/B | Schimbă |
|---|---|---|
| 2026 (TTM) | 4.68 | 87.95% |
| 2024 | 2.49 | 8.59% |
| 2023 | 2.29 | -64.95% |
| 2022 | 6.54 | 50.19% |
| 2021 | 4.36 | 38.82% |
| 2020 | 3.14 | 20.72% |
| 2019 | 2.60 | -133.37% |
| 2018 | -7.79 | -93.20% |
| 2017 | -114.62 | 0.00% |
Raport P/B pentru companii similare sau competitoare
| Companie | Raport P/B | Diferență raport P/B | Țara |
|---|---|---|---|
| 6.251 | 33.57% |
US
|
|
| 13.2547 | 183.22% |
US
|
|
| 4.208 | -10.09% |
AU
|
|
| - | - |
CH
|
|
| 6.1824 | 32.10% |
NL
|
